Abstract
Juniperus brevifolia (Seub.) Antoine (Cupressaceae) is an endemic conifer of the Azores, a habitat isolated from the continental masses which may significantly influence the biosynthesis of bioactive compounds with unique features. In this context, the toxicity, antibacterial, antioxidant (DPPH) and anti-acetylcholinesterasic (anti-AChE) activities of the methanol and acetone extracts of J. brevifolia wood and bark were evaluated for the first time. In the brine-shrimp assay all the extracts showed low toxicity, with the concentration causing 50% mortality (LC50) higher than 2.03 mg/mL. The acetone extract of the bark proved to be the most active against Bacillus cereus, B. subtilis and Micrococcus luteus, while the wood acetone extract showed activity only against B. cereus. No activity was observed against Gram (-) bacteria Escherichia coli and Enterobacter cloacae. The acetone extract of bark was the most active showing the higher antioxidant (EC 50 =7.0 µg/mL) and antiAChE activities (IC50=193 µg/mL), near to the reference compounds, quercetin (EC50=3.2 µg/mL) and ursolic acid (IC50=190 µg/mL), respectively. The present study demonstrates the great potential of the acetone bark extract of J. brevifolia as a source of new non-toxic natural bioactive compounds as antioxidant and antiacetylcholinesterasic drugs.
Highlights
The genus Juniperus is the only genus from the Cupressaceae family that grows spontaneously in Europe [1]
Acetylcholinesterase inhibitors (AChEI) have lately become a very active research topic because they increase the level of acetylcholine (ACh), which is abnormally low in disorders associated with cognitive processes, memory and neuromuscular activity [4]
The methanolic and acetone extracts from wood and bark of J. brevifolia were assayed as AChE inhibitors and the results are presented on Table 1
Summary
The genus Juniperus is the only genus from the Cupressaceae family that grows spontaneously in Europe [1]. Natural products have made significant contributions towards the treatment of degenerative diseases [3]. Acetylcholinesterase inhibitors (AChEI) have lately become a very active research topic because they increase the level of acetylcholine (ACh), which is abnormally low in disorders associated with cognitive processes, memory and neuromuscular activity [4]. Due to this fact, AChEIs have application in the treatment of Alzheimer’s disease [5], to combat myasthenia gravis, glaucoma, and as antidotes to toxins [6]. The research on new natural AChEIs and radical scavenging agents is considered very important to pharmaceutical, cosmetic and food industries
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have